Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus rating of “Buy” by the twelve brokerages that are presently covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $57.73.

A number of analysts have recently weighed in on MIRM shares. Leerink Partners upped their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Insider Activity

In other news, SVP Jolanda Howe sold 2,500 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now owns 2,426 shares in the company, valued at $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the period. Amalgamated Bank lifted its stake in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the period. Arizona State Retirement System raised its stake in Mirum Pharmaceuticals by 10.6% during the 2nd quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock worth $315,000 after acquiring an additional 883 shares during the period. Quest Partners LLC raised its stake in Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Mirum Pharmaceuticals by 11.7% during the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after acquiring an additional 1,825 shares during the period.

Mirum Pharmaceuticals Stock Up 1.6 %

NASDAQ:MIRM opened at $42.09 on Wednesday. The firm’s 50-day moving average price is $40.14 and its 200-day moving average price is $36.37. The company has a market capitalization of $2.02 billion, a PE ratio of -20.84 and a beta of 1.16. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) EPS. On average, equities analysts predict that Mirum Pharmaceuticals will post -1.51 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.